Cell-derived microparticles are supposed to be involved in endothelial dysfunction and atherogenesis. This study aimed to evaluate circulating microparticles in diabetic subjects with erectile dysfunction (ED) and their relation with endothelial dysfunction. Thirty diabetic men with ED and 20 age-matched control subjects without ED were assessed for circulating microparticles and endothelial dysfunction. Flow cytometry was used to assess microparticles by quantification of circulating endothelial (EMP, CD31 þ /CD42b À ) and platelet (PMP, CD31 þ /CD42b þ ) microparticles in peripheral blood. Endothelium-dependent flow-mediated dilation (FMD) was evaluated in the right brachial artery after reactive hyperemia. Compared with non-diabetic subjects, diabetic men presented significantly higher numbers of EMP (P ¼ 0.001), and reduced FMD (P ¼ 0.01), with a significant inverse correlation between the number of circulating EMP and the International Index of Erectile Function (IIEF) score (r ¼ À0.457, P ¼ 0.01). Multivariate analysis correcting for age, anthropometric indices, glucose and lipid parameters, FMD and PMP identified EMP as the only independent predictor for IIEF score (P ¼ 0.03). EMP are elevated in impotent diabetic subjects and independently involved in the pathogenesis of ED.
Introduction
Erectile dysfunction (ED) has an estimated incidence of 20-75% in diabetic men who are approximately three times as likely to have ED as non-diabetic men. 1, 2 The relative risk of ED increases with diabetes duration, poor glycemic control and the number of other complications present, including microvascular complications such as nephropathy, neuropathy and retinopathy, and macrovascular atherosclerosis. [1] [2] [3] One common denominator for these diseases is vascular endothelial dysfunction, and ED may be a marker for the potential development of vascular disease including myocardial infarction. [4] [5] [6] Vascular endothelium plays a pivotal role in pathogenesis of numerous thrombotic and inflammatory disorders. 7 In recent years, the interest for endothelial cell-derived submicroscopic membranous vesicles, termed microparticles, has substantially increased, not only because of their procoagulant properties but also because of their putative role in inflammatory processes and their ability to directly affect endothelial functions. [8] [9] [10] Elevated numbers of circulating microparticles have been found in patients with a great variety of diseases with vascular involvement and hypercoagulability. [11] [12] [13] [14] [15] To the best of our knowledge, there are no reported studies that evaluated circulating microparticles in impotent diabetic men. Therefore, the aims of this study were (a) to evaluate circulating endothelial (EMP) and platelet microparticles (PMP) in diabetic men with ED, (b) to address the relation between circulating microparticles and the severity of ED and (c) to assess the relation between circulating microparticles and endothelial dysfunction.
Materials and methods

Patient selection
We studied 30 type 2 diabetic subjects with symptomatic ED from at least 6 months, manifested as a persistent inability to attain and maintain an erection sufficient to permit sexual activity. 16 Diabetic men presented for routine follow-up to the Diabetes Clinics and then referred to the Center for Metabolic Diseases at the Teaching Hospital of the University of Naples SUN. To be enrolled in the study, diabetic subjects had to have no clinical evidence of any peripheral vascular disease, coronary heart disease or psychological disorder, and no previous use of drugs for ED. Impaired renal function, including macroalbuminuria, pelvic trauma, prostatic disease, non-diabetic neuropathy, proliferative retinopathy and other ED risk factors, such as use of drugs or alcohol, were also considered exclusion criteria. Erectile function was assessed by completing the International Index of Erectile Function (IIEF)-5 which consists of Items 5, 15, 4, 2 and 7 from the full-scale IIEF-15. 17 A score of 21 or less indicates the presence of ED. The abbreviated score was used for its simplicity and immediacy. A group of non-diabetic potent men matched for age with diabetic subjects were recruited from the medical and paramedical staff and served for internal reference. All subjects gave informed consent to participate in the study that was approved by the institutional review board.
Blood samplings and flow cytometry Blood was drawn into citrate vacutainers in the morning time after an overnight fast. Samples were processed within 2 h after being obtained; samples were centrifuged for 10 min at 160 g to prepare platelet-rich plasma, then centrifuged for 10 min at 900 g to prepare platelet-poor plasma. Microparticles were measured by flow cytometry. In brief, 50 ml of platelet-poor plasma was incubated (20 min) with either 4 ml of anti-CD31-FITC (BD-Pharmingen, San Diego, CA, USA), plus 4 ml anti-CD42b-PE (Becton Dickinson, San Jose, CA, USA), then diluted with 1 ml of phosphate-buffered saline and analyzed on BD FACSCalibur cytometer. EMP were defined as CD31 þ /CD42b À particles smaller than 1.5 mm, whereas PMP were defined as CD31 þ /CD42b þ particles smaller than 1.5 mm. Events were counted by triggering on the fluorescence signal of phycoerythrin, above background noise, on the y axis of the dot plot, whereas the green signal of CD31-FITC was on the x axis (four-decade log scales, x and y). Values were reported as counts per microliter. Figure 1 shows representative fluorescence-activated cell sorting (FACS) analysis for EMP and PMP.
Endothelium-dependent vasodilation
Endothelium-dependent flow-mediated dilation (FMD) was evaluated in the right brachial artery with a high-resolution ultrasound machine (Aloka 5500, Tokio, Japan) and in temperature-controlled room (21-241C). Reactive hyperemia was induced by inflation of a pneumatic cuff on the upper arm to suprasystolic pressure, followed by cuff deflation after 4.5 min. The brachial artery was scanned in longitudinal sections 2-8 cm above the elbow, and the arterial diameter was measured on B-mode images using ultrasonic calipers. The end-diastolic arterial diameter was measured from one mediaadventitia interface to the other at the clearest section, three times at baseline and every 20 s after reactive hyperemia. The maximum vessel diameter was defined as the average of the three consecutive maximum diameter measurements after hyperemia. Vasodilation was calculated as the percent change in diameter compared with baseline. The same experienced operator carried out all the studies with an intraobserver variation below 5%. 
Results
The baseline clinical and metabolic characteristics of participants in the study are shown in Table 1 . The average age was not different between diabetic and non-diabetic subjects, as were anthropometric parameters, including body mass index (BMI) and waist values. Compared with control subjects, diabetic men had greater prevalence of hypertension and hyperlipidemia, an impairment of FMD and higher levels of circulating EMP. There was a significant inverse correlation between the number of circulating EMP and the IIEF score (Figure 2 ), but not between circulating PMP and IIEF (r ¼ À0.20, P ¼ 0.28). Moreover, there was a positive correlation between FMD and IIEF (r ¼ 0.29, P ¼ 0.04). Age (r ¼ À0.16, P ¼ 0.39), BMI (r ¼ 0.296, P ¼ 0.1), waist (r ¼ À0.01, P ¼ 0.9), blood pressure (r ¼ À0.08, P ¼ 0.67), glucose (r ¼ 0.19, P ¼ 0.29), total cholesterol (r ¼ 0.07, P ¼ 0.68) and triglycerides (r ¼ 0.03, P ¼ 0.87) did not correlate with IIEF. Figure 3 shows an increase in circulating EMP across categories of IIEF. Diabetic subjects were divided into three groups according to the IIEF score Figure 4 shows the level of IIEF and EMP in the diabetic subjects divided for the presence/absence of the metabolic syndrome. A diabetic man was considered to be affected by the metabolic syndrome if he had at least other two risk factors, including a waist higher than 102 cm, hyperlipidemia (total cholesterol 4200 mg/dl, or triglycerides 4200 mg/dl, or on treatment with lipid-lowering drugs) and hypertension (blood pressure higher than 130/85 mm Hg, or on treatment with antihypertensive drugs). There was no difference between the two groups (diabetic men with or without the metabolic syndrome) as IIEF and EMP levels were concerned.
In Table 2 , univariate and multivariate analyses of correlation of IIEF with circulating EMP and endothelial-dependent vasorelaxation are reported. Multivariate analysis correcting for age, anthropometric indices, lipid and glucose parameters, FMD and PMP identified EMP as the only independent predictor for IIEF. The same result was obtained when the multivariate analysis included categorical variables such as microalbuminuria (albumin excretion rate between 20 and 200 mg/min).
Discussion
The results of the present study demonstrate that circulating endothelial-derived microparticles are higher in impotent diabetic men as compared with age-matched non-diabetic potent men, and also negatively correlated with the severity of ED. As in multivariate analysis EMP remained the only independent predictor of IIEF, it seems likely that EMP may represent a link between diabetes and ED.
To the best of our knowledge, this is the first demonstration that circulating microparticles are elevated in diabetic men with ED. Moreover, we also demonstrated that the associated risk factors present in diabetic subjects influenced neither the severity of ED nor the level of EMP. In fact, there was no significant difference in the level of both IIEF and EMP in diabetic men with or without the metabolic syndrome, suggesting that the associated risk factors do not play a major role in this respect once diabetes is present. Moreover, FMD was associated with IIEF in univariate analysis, but the significance disappeared in multivariate analysis, indicating that the level of EMP may represent the link between endothelial dysfunction and ED, at least in this population of diabetic subject with ED.
Microparticles are small membrane vesicles that are released from cells upon activation or during apoptosis. 18 The majority of in vivo microparticles in blood are derived from platelets, whereas microparticles from erythrocytes, granulocytes, monocytes, lymphocytes and endothelial cells usually circulate at lower numbers. Because of their procoagulant properties and also because of their capability to affect the endothelium functions, microparticles have been subjected to increasing attention during last years. An increase in EMP levels has been demonstrated in patients with cardiovascular disease, such as acute coronary syndromes, diabetes, hypertension and hypertriglyceridemia. [19] [20] [21] [22] [23] Microparticles can also influence endothelial functions: microparticles from patients with acute coronary syndromes directly impaired endothelium-dependent vasodilatation in rat aorta rings, presumably by inhibition of the nitric oxidemediated signal transduction. 9, 10 Although microparticles are elevated in condition of endothelial 24 Endothelial cell dysfunction may be detected clinically by measuring impairment of endotheliumdependent vasodilation 25 or by determining the plasma levels of circulating soluble markers. 26 These methods, however, are either relatively nonspecific, complicated or operator-dependent. 27 A therapeutic strategy based on the concept of vascular protection would be valuable for preventing cardiovascular events and, accordingly, there is a need to establish a practical and quantitative marker of endothelial cell dysfunction and/or injury. The recognition of a role of microparticles may not only be important for our understanding of the pathogenesis of cardiovascular diseases, but may also have implications for the prevention and treatment of these diseases. This raises the possibility that the circulating level of EMP may be a clinical surrogate marker of in vivo endothelial cell dysfunction and/or injury and cardiovascular disease. 28 Flow cytometry has the advantage to be less operator-dependent, to have a great sensitivity and to be fast, given a skilled preparation of the sampling for analysis. In order to reduce the possibility of autoactivation of platelets and hence a significant increase of PMP, blood samplings were processed within 2 h after being obtained.
The etiology of ED in diabetic patients can be multifactorial, involving mainly vascular, neurological and pharmacological factors. [1] [2] [3] Furthermore, individuals with diabetes may have other co-morbid conditions that are associated with ED without diabetes, such as renal failure, hypertension and chronic liver disease, making the precise association of diabetes with ED circumstantial under these conditions. On the other hand, our findings that EMP remain the sole predictor of ED in our diabetic subjects with ED, and the evidence that common risk factors, such as hyperlipidemia and hypertension, do not interfere with the association between EMP and ED suggest that EMP may be one important link between endothelial dysfunction and ED.
In conclusion, our findings show that EMP are elevated in impotent diabetic subjects and independently involved in the pathogenesis of ED. Whether assessment of circulating EMP may be a novel marker for ED or a target for novel therapeutic options remain to be defined in future investigations.
